Established in 2020, Plaisance Capital Management, LLC identifies and invests in biotechnology startups capable of making important differences in life science.
We work with world-class scientists, doctors, and entrepreneurs to bridge the gap between laboratory and clinic, and to accelerate breakthrough discoveries and novel therapies to clinical trials and patient beds.
A medical urgency is a humanitarian urgency.
As the COVID-19 pandemic ravaged the world, bioscience has become more critical than ever. Medical advancement and patient welfare prove to have implications far beyond the healthcare field. Quicker, more efficient paths to health recovery serve a vital role in our society’s prosperity and stability.
Plaisance is committed to empowering new treatment options and technology that advance the well-being of humanity. Through financial investment and consultation on pragmatic application, we seek to propel scientific research from theory to practice.
The collective expertise of our team and advisors ensures that our investment approach is guided by science.
Our research-driven investment procedure allows us to identify projects where we can provide the most effective assistance and resources for scientific founders and entrepreneurs.
Zhanpeng “Frederic” Jiang
Frederick is the co-founder and Managing Member of Plaisance Capital Management LLC, and serves on the board of directors of the Plaisance Venture Fund. He brings to Plaisance 26 years of capital market and management experience gained through his investment and entrepreneurial career.
Before co-founding Plaisance Capital, Mr. Jiang was the co-founder and Managing Partner of Coalescence Partners, a private equity and hedge fund management company based in Boston with offices in New York, Kansas City, and Beijing. Mr. Jiang separated from Coalescence in 2019 to focus solely on biotechnology venture investment and startup management.
Through his 26 years of investment career, Mr. Jiang has invested in many biotech, medical device, and pharmaceutical companies globally, including: Celltrion Healthcare, Chipscreen Biotechnologies, Sun Pharma, Applied StemCell, Sinobiopharm, Lifetech Scientific, MitrAssist Ltd, Clover Health, HebeCell, among others. Mr. Jiang co-founded two biotechnology startups with cutting-edge technologies, Elixell Therapeutics Inc and AccuraDX Inc, which are based in Kansas City and Chicago. Mr. Jiang currently serves as the Chairman of the Board and Acting CEO of Epican Technologies, which focuses on developing cancer early detection, diagnosis and prognosis using cf-DNA and 5hmC technologies.
Dr. Ye Fu
Joining Plaisance in 2020, Ye Fu specializes in exploring innovative ideas and developing scientific strategies to create breakthrough companies. Ye has broad multidisciplinary training at the interface of Biology, Chemistry, and Biophysics.
Prior to joining Plaisance, Ye was a postdoctoral researcher in the lab of Xiaowei Zhuang at Harvard University, where he used quantitative imaging and super-resolution imaging to study the function of RNA m6A-binding proteins in regulating the phase-separation of stress granules in mammalian cells.
Ye completed his graduate work in the lab of Chuan He at the University of Chicago, where he pioneered the work on RNA modifications and co-discovered the function of FTO as the first RNA m6A demethylase in 2011—a landmark in the field of epitranscriptomics. In addition, he developed high-throughput sequencing methods to map the genome-wide distribution of several base modifications—including 6mA and 5hmC in the eukaryotic genomes—and revealed their functions in regulating gene expression. His work in DNA and RNA modifications have greatly impacted therapeutics development and diagnosis. Additionally, he performed undergraduate research in developing Gold and Palladium-catalyzed C-H bond functionalization reactions and applications in the total synthesis of small molecules.
Ye holds a Ph.D. and M.S. in Chemistry from the University of Chicago and a B.S. in Chemistry from Peking University in China. He has published more than 25 peer-reviewed publications, including first author articles in the journal Cell, Nature Chemical Biology, as well as Nature Reviews Genetics. His work has been cited more than 12,000 times.
Dr. Wendy Liu
Wendy joined Plaisance Capital in 2022 as a senior associate. Wendy brought to Plaisance many years of experience in business development and project management. She is familiar with the entire workflow of drug discovery from target validation to IND filing.
Prior to joining Plaisance, she served as the Director of Business Development at WuXi AppTec, and was taking care of biotech portfolio management for the Northeast region. Wendy has worked with 500+ biotechs and pharmaceutical companies, and was actively engaging 150+ companies on an annual basis. She has supported the growth of many companies from idea stage to clinical settings and beyond.
Wendy holds a Ph.D. from Georgia Institute of Technology, a M.S. from Washington University in St. Louis. Her research was focused on regenerative medicines in musculoskeletal system and nerve repair.
Nancy Qin holds over 10 years of experience in Sino-U.S. coordination and international entrepreneurship. She was the former international business manager for the fintech company Intop Technology Group, overseeing all China-U.S. communications with partners and service providers. Before that, she was the investor relations manager and corporate communications manager at American Education Center (AMCT), curating intercultural events and coordinating public communications.
In addition to her know-hows in the corporate world, Nancy is also a seasoned translator of business, educational, and historical materials. She is the co-translator for the English edition of An Outline of Chinese Traditional Philosophy (2015), a graduate school level textbook by Dr. Cunshan Li of the Chinese Academy of Social Sciences. Most recently, she is the translation team coordinator of the Chinese edition of Frankie Manning: Ambassador of Lindy Hop (Manning & Millman, 2020).
Dr. Chuan He
Advisory Board Member
Dr. Chuan He is a world-renowned chemist currently serving as the John T. Wilson Distinguished Service Professor of chemistry, biochemistry, and molecular biology at the University of Chicago, and an Investigator of the Howard Hughes Medical Institute. He is best known for his work in discovering and deciphering reversible RNA methylation in post-transcriptional gene expression regulation.
Dr. He graduated from the University of Science and Technology of China in 1994 with a B.S. in Chemistry. After his Ph.D. training with Stephen J. Lippard at the Massachusetts Institute of Technology, he worked under Gregory L. Verdine as a Damon Runyon Postdoctoral Fellow at Harvard University. He became a faculty member in the Department of Chemistry at the University of Chicago in 2002.
Dr. Xiang-Dong Fu
Advisory Board Member
Dr. Xiang-Dong Fu is Distinguished Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).
Dr. Fu was responsible for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to AAAS Fellow (2010).